European Commission approves update of Erbitux
Merck Serono announced that the European Commission has approved the Type II variation to amend the Erbitux® (cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC). The approval of the European Commission follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) (issued in November 2013) and is based on the totality of data emerging on the role of mCRC RAS tumor status in the benefit–risk profile of the drug. The approval primarily refers to new biomarker data from the OPUS (oxaliplatin and cetuximab in firSt-line treatment of mCRC) study.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Robert_Charles_Moon

New vaccine concept against SARS-CoV-2 successfully tested - University of Basel and biotech start-up RocketVax present a vaccine concept that could lead to a new generation of vaccines
VTT identified specific bacteria which precede autoimmune diabetes - New potential avenues for early disease detection and prevention
Langerhans_cell_histiocytosis

Putting an end to rheumatoid arthritis? - Interdisciplinary research team unlocks the mechanism for inhibiting inflammation of the joints
Protein_biosynthesis
